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Abstract The etiology of hypertension, a critical public health
issue affecting one in three US adults, involves the integration
of the actions of multiple organ systems, including the central
nervous system. Increased activation of the central nervous
system, driving enhanced sympathetic outflow and increased
blood pressure, has emerged as a major contributor to the path-
ogenesis of hypertension. The hypothalamus is a key brain site
acting to integrate central and peripheral inputs to ultimately
impact blood pressure in multiple disease states that evoke
hypertension. This review highlights recent advances that have
identified novel signal transduction mechanisms within multi-
ple hypothalamic nuclei (e.g., paraventricular nucleus, arcuate
nucleus) acting to drive the pathophysiology of hypertension in
neurogenic hypertension, angiotensin II hypertension, salt-
sensitive hypertension, chronic intermittent hypoxia, and
obesity-induced hypertension. Increased understanding of hy-
pothalamic activity in hypertension has the potential to identify
novel targets for future therapeutic interventions designed to
treat hypertension.
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Introduction
Hypertension, a significant public health issue, affects one third
of the US adult population and is a critical risk factor for future
adverse cardiovascular events—significantly contributing to the
burden of cardiovascular and kidney disease, stroke, and prema-
ture death and disability [1]. As a heterogenous disease, the
pathogenesis of hypertension has remained elusive but likely
involves the complex integration of multiple regulatory systems.
Recent work has explored the role of brain mechanisms in both
the short- (i.e., initiation) and long-term (i.e., maintenance) con-
trol of blood pressure as increasing evidence implicates activa-
tion of the central nervous system as a key contributor to the
development of hypertension [2]. The hypothalamus is an essen-
tial component in the regulatory neural network of central blood
pressure control serving to coordinate and integrate signal trans-
duction in response to central and peripheral stimuli [3]. The
hypothalamus acts as the interface between the endocrine and
nervous systems, and a wide variety of functional changes in the
hypothalamus characterize multiple forms of hypertension.
Highlighting the importance of central pathways regulating
blood pressure, it has been suggested that more than 50 % of
clinical hypertension cases can be categorized as neurogenic
essential hypertension [4]. Therefore, a more detailed under-
standing of dysfunctional reflexes and/or altered neural circuitry
within the hypothalamus will potentially reveal novel targets for
future therapeutic intervention to treat hypertension. The purpose
of this review is to highlight recent advancements in our under-
standing of signal transduction pathways within the hypothala-
mus that impact the etiology and pathogenesis of hypertension.
This article is part of the Topical Collection on Hypertension and the
Brain




1 Department of Pharmacology & Experimental Therapeutics and The
Whitaker Cardiovascular Institute, Boston University School of
Medicine, 72 East Concord St, Boston, MA 02118, USA
Curr Hypertens Rep (2015) 17: 39
DOI 10.1007/s11906-015-0550-4
Advances in Hypothalamic Neuronal Signaling
in Hypertension
Increased neuronal activity and excitability (i.e., synaptic plas-
ticity) in the hypothalamic paraventricular nucleus (PVN) me-
diates elevated sympathetic drive in multiple hypertensive an-
imal models. Recent work has focused on identifying the syn-
aptic mechanisms driving increased PVN neuronal activity. In
the Spontaneously Hypertensive Rat (SHR) model of neuro-
genic hypertension, patch-clamp electrophysiological studies
conducted in brain slices have revealed that there is increased
activity of spinally projecting PVN presympathetic neurons
[5–7] and preautonomic PVN neurons that innervate the nu-
cleus tractus solitarius [8]. Increased excitability of
preautonomic PVN neurons is primarily mediated by an
input-output function in response to depolarizing stimuli [8].
PVN presympathetic neuron tone is regulated by excitatory
and inhibitory GABAergic inputs. The polarities of the actions
of γ-aminobutyric acid (GABA) on the GABAA receptor, a
ligand-gated ion channel, are strongly influenced by intracel-
lular chloride concentrations. In the SHR, dysregulation of the
intracellular chloride homeostasis of PVN presympathetic
neurons is evoked by upregulation and glycosylation of the
Na+-K+-2Cl− cotransporter 1 (NKCC1) [5], and this contrib-
utes to the impaired PVN GABAergic synaptic inhibition and
increased sympathetic tone observed in the SHR. Additional-
ly, impairment of PVN GABAergic inhibitory signaling has
been observed in vivo in a mouse model of neurogenic hyper-
tension (the Schlager mouse). This alteration of GABAergic
signaling is postulated to contribute to Schlager mouse hyper-
tension through reduced PVN inhibitory drive to
presympathetic neurons [9].
Highlighting the complexity of PVN glutamatergic path-
ways on the activity of spinally projecting PVN neurons are
the opposing actions of group I and group II metabotropic
glutamate receptors (mGluRs). The activity of group II
mGluRs at PVN glutamatergic terminals, determined via
patch-clamp studies in isolated brain slices, is enhanced in
the SHR [6]. This elevated activation of mGluRs attenuates
increased glutamatergic input via a negative feedback path-
way to reduce presympathetic PVN neuronal hyperactivity. In
companion in vivo PVN microinjection studies, mGluR acti-
vation evoked reductions in sympathetic vasomotor tone and
blood pressure in the SHR [6], suggesting that activation of
PVN group II mGluRs attenuates elevated glutamateric inputs
and neuronal hyperactivity in the SHR. In contrast, deter-
mined in hypothalamic slices, increased endogenous expres-
sion of the group I mGluR5 in the PVN of the SHR drives
increased basal firing of spinally projecting PVN neurons [7].
In vivo studies provide evidence that the mechanism underly-
ing mGluR5-driven hyperactivity of PVN presympathetic
neurons in the SHR involves recruitment of N-methyl-D-as-
partate (NMDA) receptors to the cell surface. This occurs via a
protein kinase C (PKC) and synaptosomal-associated protein-
mediated signal transduction pathway to increase NMDA
receptor-mediated activity and subsequently sympathetic tone
and blood pressure [7].
Increased presympathetic PVN neuron firing in the SHR,
assessed in hypothalamic slices, is driven in part by anNMDA
receptor-calpain-calcineurin signaling pathway that evokes
glutamate receptor 2 (GluR2) internalization, determined
in vivo, increasing the activity of GluR2-lacking α-Amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) re-
ceptors [10]. In addition to altering AMPA receptor activity,
the NMDA receptor directly increases glutamatergic activity
in the SHR. Potentiated pre- and postsynaptic PVN NDMA
receptor activity, determined via brain slice electrophysiolog-
ical studies, is mediated by upregulation of synaptic GluN2A,
an NMDA receptor subunit, that is dependent on PKCK2
activity [11]. PKCK2 also influences the activity of the small
conductance calcium-activated K+ (SK) channel in the PVN.
The SK channel impacts the intrinsic activity of
presympathetic PVN neurons, and SK activity is reduced in
the SHR via a CK2-mediated calmodulin phosphorylation
mechanism [12]. Clinical trials are currently investigating
the safety of CK2 inhibitors, which may have a future thera-
peutic application to reduce sympathetic outflow via the mod-
ulation of the activity of SK channels and NMDA receptors. A
critical issue facing the field, which remains to be fully ad-
dressed, is the potential difference in synaptic activity in vivo
versus the measurements made in brain slices in which syn-
aptic connections and synaptic drive are lost. Owing to con-
siderable technical impediments, despite the significant in-
sight provided via electrophysiological patch-clamp studies
conducted in PVN neuron containing brain slices [5–8,
10–12], our understanding of PVN neuronal synaptic activity
in vivo in hypertensive animals models remains limited.
The hypothalamic arcuate nucleus (ARCN) dramatically
impacts cardiovascular function and sympathetic outflow
in vivo [13, 14, 15•]. At normal blood pressures, NMDA
activation of the ARCN in Wistar rats evokes decreases in
blood pressure and splanchnic nerve activity mediated by
PVN GABAA, neuropeptide Y1, and opioid receptors [13].
Significantly, if blood pressure is lowered, NMDA stimulation
of the ARCN evokes increases in blood pressure mediated by
PVN melanocortin receptors [13]. In the Wistar rat,
barodenervation studies reveal that interruption of the barore-
ceptor afferents is responsible for converting NMDA-evoked
melanocortin and ionotropic glutamate receptor mediated
ARCN cardiovascular and sympathetic depressor actions into
pressor responses [14]. In the baro-intact hypertensive SHR,
which exhibits attenuated ARCN baroreceptor and
GABAergic function [15•], NMDA activation of the ARCN
evokes elevations in blood pressure and splanchnic nerve ac-
tivity, as observed in the barodenervatedWistar rat [15•]. Col-
lectively, these data highlight the previously unknown role of
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the ARCN in the regulation of blood pressure and sympathetic
activity in normotensive and hypertensive phenotypes in vivo.
The potential impact of ARCN signal transduction in other
cardiovascular disease states featuring increased blood pres-
sure (e.g., obesity, salt-sensitive hypertension) remains to be
established.
Advances in Hypothalamic Inflammatory Pathways
in Hypertension
Increased hypothalamic expression of proinflammatory cyto-
kines (PIC) is closely associated with the pathophysiology of
hypertension. In particular, multiple studies have demonstrat-
ed an interaction between the renin-angiotensin system
(RAS)-mediated hypertension and inflammation [16]. Nucle-
ar factor-κB (NFκB) is a key transcription factor governing
inflammatory processes and plays a critical role in mediating
inflammation-induced hypertension. Blockade of NFκBwith-
in the PVN significantly attenuates angiotensin II (Ang II)-
induced hypertension—a response accompanied by a reduc-
tion in PIC and upregulation of the protective anti-
hypertensive arms of the RAS system [17]. A subsequent
study revealed PVN specific blockade of tumor necrosis fac-
tors (TNF) significantly attenuates Ang II-evoked hyperten-
sion and increases in PIC and prevented Ang II-evoked de-
creases in pro-hypertensive RAS components. This highlights
a key role of TNF in Ang II-stimulated inflammation [18].
Illustrating the cross talk between reactive oxygen species
(ROS) and PIC signal transduction pathways, central admin-
istration of the ROS scavenger tempol attenuates Ang II in-
creases in PVN interleukin (IL) 1β, sympathetic activity, and
blood pressure [19]. Despite the clear involvement of Ang II
in stimulating PIC, the pathways that initiate this response
remain to be fully defined. Disruption of PVN p44/42
mitogen-activated protein kinase (MAPK) signal transduction
during the early phase of slow pressor Ang II infusion, prior to
the development of hypertension, attenuates Ang II hyperten-
sion and sympathoexcitation, but does not reduce Ang II-
evoked increases in PIC [20]. In the deoxycorticosterone
acetate-salt (DOCA-salt) model of neurogenic hypertension,
overexpression of angiotensin-converting enzyme 2 (ACE2)
attenuates hypertension and reverses DOCA-salt-induced in-
creases in PVN extracellular signal regulated kinase (ERK)
and cyclooxygenase 1-mediated inflammation [18]. This sug-
gests a role for ERK pathways in the Ang II-evoked inflam-
matory pathway that contributes to hypertension.
Recent evidence supports a novel direct action of prorenin,
another key component of the RAS system, to activate PVN
microglia that drives proinflammatory signaling and hyperten-
sion [21]. The actions of Ang II to drive inflammation also
occur in obesity-induced hypertension, a complex model of
hypertension, in which PVN-specific angiotensin type 1
receptor (AT1AR) deletion attenuates hypothalamic inflamma-
tion and high-fat diet induced increases in blood pressure [22].
In contrast to the body of evidence presented above, it was
recently reported that model that blockade of PVN TNFα
does not reduce blood pressure or sympathetic nerve activity
in the Ang II-salt hypertension [23]. These conflicting data
highlight that our understanding of the role of inflammation
in the regulation of blood pressure is far from complete.
Advances in Hypothalamic Oxidative Stress
Pathways in Hypertension
Within the PVN, ROS modulates sympathetic nerve activity
and the development of hypertension. Virally mediated over-
expression of PVN superoxide dismutase (SOD1) significant-
ly attenuates hypertension, sympathetic activity, and the car-
diac sympathetic afferent reflex (CSAR) in the SHR rat [24].
PVN-specific inhibition of ROS, achieved by bilateral PVN
infusion of the free radical scavenger tempol, attenuates intra-
venous Ang II - induced hyper tens ion and rena l
sympathoexcitation [19]. Further, abolishment of Ang II me-
diated increases in PVN ROS, and blood pressure are ob-
served following PVN-specific NFκB inhibition [17]. Both
of these studies [17, 19] support the hypothesis that Ang II-
generated intra-PVN ROS contributes to the pathophysiology
of Ang II hypertension. During slow pressor Ang II hyperten-
sion, increased membrane mobilization of the nicotinamide
adenine dinucleotide phosphate oxidase subunit (NOX)
p47phox correlates with increased ROS production in PVN
neurons. This suggests an influence of Ang II to drive mobi-
lization of cytoplasmic nicotinamide adenine dinucleotide
phosphate (NADPH) p47phox stores to increase oxidative
stress [25]. Additionally, slow pressor Ang II-mediated pro-
duction of ROS reduces PVN nitric oxide (NO) signal trans-
duction and increases glutamatergic signaling—a change pos-
tulated to contribute to neural dysfunction in this model of
hypertension [25]. Interestingly, the temporal impact of
changes in NO signaling in the pathophysiology of hyperten-
sion remains relatively unexplored. Partially addressing this
knowledge gap, it has been reported that reductions in PVN
NO activity that occur during the onset of hypertension in the
renal wrap hypertensive rat model may act as a trigger event
for the development of hypertension [26].
Improved NO signaling attenuates hypertension in animal
models—experimental data that demonstrate that exploiting
the anti-hypertensive actions of NO represents a potential
treatment modality for hypertension. In the 2-kidney 1-clip
(2K1C) rat, activation of PVN adrenomedullin receptors by
exogenous intermedin evokes decreased renal sympathetic
nerve activity and long-term reductions in the magnitude of
hypertension by increasing the availability of NO metabolites
[27]. In DOCA-salt hypertension, neuron-targeted
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overexpression of ACE2 increases PVN levels of SOD and
manganese SOD and attenuates DOCA-salt-evoked oxidative
stress leading to attenuation of neurogenically mediated hy-
pertension [18]. The recent advances detailed above highlight
the involvement of oxidative stress pathways in multiple
forms of hypertension, and suggest that further investigation
of these mechanisms may result in the discovery of new ther-
apeutic avenues for hypertension treatment.
Advances in Hypothalamic Regulation
of Vasopressin Secretion in Hypertension
Although the role of arginine vasopressin (AVP) in hyperten-
sion remains under debate, increasing evidence implicates el-
evated AVP in the pathogenesis of several forms of human
hypertension. Recent studies in the stroke-prone SHR corre-
lated increased PVN and supraoptic nucleus (SON)
magnocellular AVP levels with both age and magnitude of
hypertension [28]. Nonetheless, the mechanisms by which
AVP levels are increased to drive or maintain hypertension
remain poorly defined. It has been hypothesized that in the
SHR, elevated hypothalamic magnocellular expression of the
mineralocorticoid receptor (MR) drives AVP release to con-
tribute to the maintenance of hypertension—a theory support-
ed byMR antagonism normalizing blood pressure in the SHR
phenotype [29]. Further, in the 2K1C model of renovascular
hypertension, AVP contributes to hypertension via a PVN-
specific salusin-β AVP-V1 receptor-dependent (Ang II-
independent) pathway [30]. This evokes increased sympathet-
ic activation, and subsequently hypertension, via downstream
signal transduction and V1 receptor activation in the rostral
ventrolateral medulla (RVLM) [30]. Extending the involve-
ment of AVP in hypertension are recent investigations
reporting that impaired GABAergic inputs to PVN and SON
vasopressin neurons may contribute to the development of
salt-sensitive hypertension. In the DOCA-salt rat model, a
gradual and progressive Binhibitory-to-excitatory^ switch in
the GABAA receptor state occurs, mediated by depolarization
of the GABA equilibrium potential. This switch is dependent
on altered intracellular chloride homeostasis in AVP neurons
that is driven by upregulation of NKCC1 and downregulation
of the K+-Cl− cotransporter isotype 2 (KCC2) [31]. This trans-
forms the canonical inhibitory GABAA receptor response into
a stimulatory drive in hypothalamic magnocellular AVP neu-
rons to increase AVP release—a switch (i.e., excitatory
GABAergic input) that may drive the development of salt-
sensitive hypertension [31]. Downregulation of PVN KCC2
is also evoked during high salt intake by brain-derived neuro-
trophic factor (BDNF) activation of a tyrosine kinase receptor
B (TrkB) pathway [32•]. KCC2 downregulation alters the
chloride gradient across SON neurons, abolishing aortic
baroreceptor-evoked GABAergic inhibition of AVP neurons.
This alteration in inputs to AVP neurons drives excessive AVP
release to trigger hypertension via peripheral V1 receptor-
mediated vasoconstriction [32•]. Collectively, these studies
provide insight into AVP signal transduction within the PVN
and SON and suggest multiple therapeutic targets to reduce
AVP release in hypertension.
Advances in Hypothalamic Signaling
in Salt-Sensitive Hypertension
Excess dietary salt intake is an established cause of hyperten-
sion resulting in an increased risk of adverse cardiovascular
events [33, 34]. At present, the mechanism(s) by which die-
tary salt evokes hypertension remain to be fully elucidated. In
t h e Dah l s a l t - s e n s i t i v e (DSS ) r a t ph eno t ype ,
sympathoexcitatory and pressor responses to increased cere-
brospinal fluid (CSF) sodium are enhanced [35]. In salt-
resistant rat phenotypes, a hypothalamic intraneuronal salt-
inducible kinase 1 (SIK1)-N+/K+ATPase activity pathway re-
duces CSF sodium-induced sympathoexcitation and increases
in blood pressure [35]. In contrast, in the DSS rat, reduced
hypothalamic SIK1 expression and activity suggests this
anti-hypertensive mechanism is downregulated and may con-
tribute to salt-sensitivity [35]. An additional mechanism con-
tributing to the maintenance of elevated blood pressure in
hypertensive DSS rats involves activation of both PVN gluta-
mate and angiotensin type 1 receptors (AT1R)—a response
that involves enhanced AT1R-mediated local glutamate recep-
tor activation [36] and is absent in normotensive DSS and
Dahl salt-resistant (DSR) rats. Further, a role of increased
brain MR receptor activation has been suggested to drive the
activation of PVN glutamate and AT1R in Ang II hypertension
in the Wistar rat [36].
It is well documented that chronic sodium intake alters
neuronal activity of the PVN; however, the temporal depen-
dency of these changes remains unclear. Acute activation of
forebrain sympathoexcitatory osmosensory inputs to the
PVN, via acute internal carotid artery infusion of hypertonic
saline and activation of glutamatergic pathways, rapidly in-
creases splanchnic and phrenic nerve activity and blood pres-
sure [37]. These studies demonstrate that acute sodium-
evoked activation of the PVN is able to drive increased vaso-
motor sympathetic nerve activity and blood pressure, suggest-
ing that PVN neural activation may be an early event in the
pathophysiology of salt-sensitivity. During chronic high salt
intake, the forebrain hypothalamus also plays a critical role in
modulating central sympathetic outflow [38]. Highlighting the
adverse impact of excess salt intake, forebrain hypothalamic
circuitry mediates sodium-evoked sensitization of sympathet-
ic responses and increased blood pressure variability in salt-
resistant Sprague–Dawley (SD) rats [38].
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A recent focus has been on the identification of potential
mechanisms maintaining salt-resistance [39–41]. In the salt-
resistant SD rat, in response to changes in dietary sodium
intake, there is an endogenous PVN-specific increase (sodium
excess) or decrease (sodium restriction) in guanine nucleotide
binding protein alpha inhibiting activity binding polypeptide 2
(Gαi2) protein expression [39]. Acute and chronic downregu-
lation of brain Gαi2 proteins in high salt-challenged SD rats,
which prevents endogenous PVN Gαi2 protein upregulation,
evokes sodium retention, global sympathoexcitation, and ele-
vated blood pressure [39, 40] suggesting a critical role of these
proteins in maintaining salt-resistance. An endogenous
sodium-evoked increase in PVN Gαi2 protein expression
has been documented in multiple salt-resistant phenotypes,
as has a failure of this response in the DSS rat [41]. Further,
brain Gαi2 proteins are required to maintain salt-resistance,
via a renal nerve-dependent pathway, in the salt-resistant SD
and DSR rat [40, 41]. Collectively, PVN-specific Gαi2-sub-
unit protein–gated signal transduction pathways represent a
novel central molecular signal transduction pathway that acts
to regulate central sympathetic outflow to the kidneys in re-
sponse to alterations in salt intake to maintain a salt-resistant
phenotype [39–41].
Advances in Hypothalamic Pathways Involved
in Chronic Intermittent Hypoxia
Chronic intermittent hypoxia (CIH), an animal model of hu-
man sleep apnea, exhibits increased blood pressure and ele-
vated sympathetic tone as is observed in the clinical pheno-
type. Central administration of losartan attenuates the
sustained component of CIH-induced hypertension [42].
Blockade of the actions of Ang II decreases FosB/ΔFosB
staining in the parvocellular regions of the PVN (and other
autonomic control sites), indicating that brain RAS contrib-
utes to increased transcriptional activation in autonomic nuclei
to drive CIH-mediated hypertension [42]. During CIH, the
contribution of PVN neuronal activity to support lumbar sym-
pathetic nerve activity (LSNA) and blood pressure is in-
creased, as is the responsiveness of PVN-mediated increases
in LSNA to hypertonic saline [43]. Further supporting a cen-
tral role of the PVN in CIH-evoked sympathoexcitation is
evidence that acute and chronic CIH modulates the excitatory
output from the PVN to brain stem parasympathetic vagal
neurons, which leads to a reduction in PVN-evoked excitatory
glutamatergic postsynaptic currents. The resulting diminished
activation of cardiac vagal neurons potentially increases the
risk of adverse cardiovascular events during episodes of sleep
apnea [44]. These data suggest that CIH-mediated hyperten-
sion features impairments in both sympathetic and parasym-
pathetic tone evoked by altered PVN neuronal activity [43,
44]. A recent clinical study provided evidence that sleep apnea
patients’ elevated spontaneous muscle sympathetic nerve ac-
tivity is related to functional changes in activity of several
cortical and subcortical regions, but did not report changes
in activity of the hypothalamus [45]. This discrepancy may
reflect differences between animal models of CIH and the
clinical phenotype.
Advances in Hypothalamic Pathways Activated
in Obesity-Induced Hypertension
The hormone leptin, released from white adipose tissue, acts
within the hypothalamus via intracellular AMP-activated pro-
tein kinase (AMPK) signaling pathways to evoke
sympathoexcitation (particularly to the kidney) and hyperten-
sion [46]. Recent discoveries have determined that hypotha-
lamic AMPKα2mediates the hypertensive and regional (renal
and adipose) sympathoexcitation evoked by central leptin
[46]. AMPKα2 therefore plays a previously unknown role
in mediating leptin-evoked increased sympathetic stimulation
of both the kidneys and adipose tissue. Extending this novel
role of leptin, it has been demonstrated that leptin also acti-
vates the mammalian target of rapamycin (mTORC1) via a
phosphoinositide 3-kinase (PI3K) pathway [47•]. Further,
mTORC1 activity is required to mediate leptin-induced
increases in renal sympathetic nerve activity (RSNA)
and blood pressure via a mechanism lying upstream of
the melanocortin receptor system [47•]. Within the hy-
pothalamus, ARCN-specific blockade of mTORC1 sig-
naling decreases baseline RSNA and blood pressure and
essentially eliminates leptin-evoked hypertension and re-
nal sympathoexcitation [47•].
Recent evidence has revealed the existence of striking sex
differences in leptin’s ability to increase sympathetic nerve
activity and blood pressure. The stimulatory effects of leptin
on blood pressure are absent in female rats [48]. Additionally,
leptin-evoked increases in LSNA and RSNA are only evident
during pro-oestrus and estrogen-treated ovariectomized fe-
male rats, and are mediated via a mechanism involving in-
creased alpha-melanocyte-stimulating hormone activation of
PVN presympathetic neurons [48]. Beyond direct sex differ-
ences, it has been documented that maternal obesity (triggered
by a high-fat diet) results in the offspring of rabbits exhibiting
increased blood pressure and RSNA [49] via a mechanism
involving increases in hypothalamic sensitivity to leptin
[49]. Collectively, these findings suggest that it may be bene-
ficial to consider both gender and maternal environment in
future studies into the mechanisms of obesity-induced
hypertension.
A direct role of insulin signaling in cardiovascular dysreg-
ulation resulting in hypertension in obesity and/or diabetes
remains controversial. However, the ARCN has been identi-
fied as a key site at which insulin evokes increases in LSNA
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[50]. Insulin-mediated stimulation of the ARCN increases
blood pressure and LSNA via a downstream pathway requir-
ing glutamate receptor activation in the PVN. Recently, it has
been documented via direct recordings of LSNA that activa-
tion of PVN glutamate receptors contributes to insulin-evoked
sympathoexcitation through an NMDA-dependent signal
transduction pathway [51]. Further, highlighting the impor-
tance of mTORC1 and PI3K signaling pathways in the regu-
lation of sympathetic nerve activity, insulin evokes activation
of LSNAvia a hypothalamic ARCN PI3K-mTORC1 pathway
[52, 53]. The sympathoexcitatory actions of insulin, centrally
or locally within the ARCN, are attenuated by glucocorticoid
administration [52] via pathway(s) located downstream of the
above-described PI3K-mTORC pathway. These molecular
studies provide new targets for therapeutic compounds to treat
the sympathetic overactivity and hypertension associated with
obesity.
Novel Paradigms in Hypothalamic Signaling
in Hypertension
Blood Brain Barrier Disruption
Ang II activates a multitude of hypothalamic signal transduc-
tion pathways to drive the pathophysiology of hypertension.
However, how circulating Ang II exerts central actions has
long been under debate, owing to the fact that under normal
physiological conditions, Ang II is unable to penetrate the
blood brain barrier (BBB). Recent data demonstrate that
Ang II impairs the integrity of the BBB in the hypothalamic
region via an AT1R mechanism in the SHR. This facilitates
elevated Ang II levels and Ang II co-localization with neurons
and glial in the PVN—sites normally protected from the ac-
tions of circulating Ang II [54••]. These data provide the first
evidence that circulating Ang II, in a hypertensive condition,
exerts direct actions in the brain in a hypertensive set-
ting, beyond the established actions on projections em-
anating from the subfornical organ that drive neurohu-
moral activation in hypertension. It remains to be
established if Ang II disrupts BBB integrity to drive
central Ang II signal transduction and increases in blood
pressure in additional hypertensive models.
Central Nervous System Sensitization
Recent evidence highlights a direct role of central nervous
system sensitization in the pathogenesis of Ang II slow pres-
sor hypertension via an AT1R mechanism [55••]. Seven days
of sensitization with a non-pressor dose of Ang II, adminis-
tered centrally or peripherally, dramatically exacerbates the
subsequent hypertensive response to slow pressor Ang II in-
fusion [55••]. Sensitization evokes increased PVN MR
receptor expression and PVN neuronal activation during slow
pressor Ang II infusion. Highlighting the interaction be-
tween aldosterone and the RAS, subpressor aldosterone
(centrally or peripherally) cross-sensitizes and exacer-
bates slow pressor Ang II hypertension via a PVN
MR receptor pathway [55••]. These data highlight the
impact of hypothalamic neuroplasticity on the patho-
physiology of hypertension—a comparatively unex-
plored field that will likely yield valuable insights into
the central regulation of blood pressure.
Anterior Hypothalamic Parvalbuminergic Neurons
A previously unknown population of parvalbuminergic neu-
rons, which require thyroid hormone signaling for proper de-
velopment, has been identified in the anterior hypothalamus
(AH) [56••]. Significantly, this neuronal population has a pro-
found impact on blood pressure regulation as ablation of these
cells evokes hypertension. The mechanism involved in in-
creasing blood pressure following ablation of AH
parvalbuminergic neurons occurs independently of alterations
in the RAS and appears to bemediated by alterations in central
autonomic function [56••]. Due to the recent discovery of this
neuronal population, the potential impact of this AH
parvalbuminergic cell population in hypertension remains to
be fully defined, as does the impact of thyroid disease on
blood pressure regulation.
Conclusion
Over the last several years, our understanding of the signaling
pathways acting within the hypothalamus to regulate blood
pressure has dramatically increased. The PVN remains a pre-
dominant site within the hypothalamus at which signal trans-
duction pathways in multiple hypertensive disease states
evoke autonomic and endocrine imbalance to drive ele-
vations in both sympathetic outflow and blood pressure.
An increasingly important role of the ARCN in blood
pressure regulation and renal nerve activity has been
revealed, suggesting this hypothalamic nucleus may play
a larger than previously thought role in the long-term
regulation of blood pressure. The next few years will
provide further delineation of hypothalamic disease-
specific signaling pathways and may identify potential
cross talk between these mechanisms across hyperten-
sion disease states. We speculate that current and future
identification of hypothalamic signaling mechanisms
will generate therapeutic targets with broad applications
to treat human hypertension.
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